BR100 Decreased By (-0.73%)
BR30 Decreased By (-0.52%)
KSE100 Decreased By (-0.55%)
KSE30 Decreased By (-0.65%)
AGHA 7.69 Decreased By ▼ -0.12 (-1.54%)
BECO 5.15 Decreased By ▼ -0.06 (-1.15%)
BML 57.50 No Change ▼ 0.00 (0%)
BOP 34.09 Increased By ▲ 0.06 (0.18%)
CNERGY 10.06 Increased By ▲ 0.10 (1%)
CSIL 5.29 Decreased By ▼ -0.02 (-0.38%)
FCCL 53.88 Decreased By ▼ -0.82 (-1.5%)
FFL 16.56 Decreased By ▼ -0.13 (-0.78%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 7.29 Decreased By ▼ -0.11 (-1.49%)
KOSM 5.77 No Change ▼ 0.00 (0%)
LOTCHEM 29.23 Decreased By ▼ -0.09 (-0.31%)
MLCF 92.48 Decreased By ▼ -1.88 (-1.99%)
NBP 201.60 Decreased By ▼ -1.45 (-0.71%)
NCPL 56.87 Decreased By ▼ -0.13 (-0.23%)
NPL 66.84 Decreased By ▼ -0.86 (-1.27%)
OGDC 315.49 Decreased By ▼ -0.35 (-0.11%)
PACE 10.56 Decreased By ▼ -0.08 (-0.75%)
PAEL 42.66 Decreased By ▼ -0.54 (-1.25%)
PIBTL 16.59 Decreased By ▼ -0.15 (-0.9%)
PPL 218.60 Decreased By ▼ -1.18 (-0.54%)
PRL 51.20 Increased By ▲ 2.01 (4.09%)
PTC 70.25 Decreased By ▼ -0.28 (-0.4%)
SSGC 27.49 Decreased By ▼ -0.76 (-2.69%)
TBL 9.79 Decreased By ▼ -0.07 (-0.71%)
TELE 8.69 Decreased By ▼ -0.10 (-1.14%)
TPL 18.35 Increased By ▲ 0.11 (0.6%)
TPLP 13.48 Increased By ▲ 0.21 (1.58%)
TREET 22.53 Decreased By ▼ -0.19 (-0.84%)
TRG 60.12 Decreased By ▼ -0.02 (-0.03%)
By

LONDON: British pharmaceutical giant AstraZeneca said Thursday that a third, or "booster", dose of its Covid-19 vaccine Vaxzevria "significantly" lifted antibody levels against the Omicron strain in a laboratory study.

"Vaxzevria significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster," the company said in a statement citing the study.

"The third dose booster vaccination neutralised the Omicron variant to levels that were broadly similar to those observed... after the second dose against the Delta variant," it said.

Levels of neutralising antibodies were also higher with the booster jab than with individuals who had previously been infected and recovered naturally from Covid-19.

The study was conducted by investigators from the University of Oxford, which is the academic institution which helped AstraZeneca develop the vaccine last year.

Moderna says full booster dose improves Omicron protection

The study analysed blood samples taken from individuals infected with Covid-19; those vaccinated with two doses plus a booster; and those who had reported previous Covid infection.

"It is very encouraging to see that current vaccines have the potential to protect against Omicron following a third dose booster," said University of Oxford professor John Bell, one of the study investigators.

"These results support the use of third dose boosters as part of national vaccine strategies, especially to limit the spread of variants of concern, including Omicron."

On Wednesday, the World Health Organization had warned that rich countries cannot use boosters to escape the Covid crisis, as they divert valuable jabs away from poorer nations -- and encourage the virus to spread and mutate.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

The threat of the highly transmissible Omicron variant is looming large over the end-of-year holidays, pushing many governments to roll out new restrictions and urge citizens to get vaccinated.

The latest data suggest Omicron does not cause more severe illness than previous variants, including Delta, but as soaring infection numbers threaten to overwhelm health systems, scientists warn it could still cause more deaths.

Comments

Comments are closed for this article.